Scholars@Duke

Chronic myelogenous leukemia, version 1.2015.

Publication ,  Journal Article
O'Brien, S; Radich, JP; Abboud, CN; Akhtari, M; Altman, JK; Berman, E; Curtin, P; DeAngelo, DJ; Deininger, M; Devine, S; Fathi, AT; Gotlib, J ...
Published in: J Natl Compr Canc Netw
November 2014
Published version (DOI) Link to item

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

Duke Scholars

Joseph Odell Moore
Author Joseph Odell Moore Medicine, Hematological Malignancies

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2014.0159

EISSN

1540-1413

Publication Date

November 2014

Volume

12

Issue

11

Start / End Page

1590 / 1610

Location

United States

Related Subject Headings

  • Protein-Tyrosine Kinases
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Leukemia, Myeloid, Chronic-Phase
  • Leukemia, Myeloid, Accelerated Phase
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Guidelines as Topic
  • Antineoplastic Agents
  • 4203 Health services and systems
 

Citation

APA
Chicago
ICMJE
MLA
NLM
O’Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., … Sundar, H. (2014). Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw, 12(11), 1590–1610. https://doi.org/10.6004/jnccn.2014.0159
O’Brien, Susan, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, et al. “Chronic myelogenous leukemia, version 1.2015.” J Natl Compr Canc Netw 12, no. 11 (November 2014): 1590–1610. https://doi.org/10.6004/jnccn.2014.0159.
O’Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, et al. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014 Nov;12(11):1590–610.
O’Brien, Susan, et al. “Chronic myelogenous leukemia, version 1.2015.” J Natl Compr Canc Netw, vol. 12, no. 11, Nov. 2014, pp. 1590–610. Pubmed, doi:10.6004/jnccn.2014.0159.
O’Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014 Nov;12(11):1590–1610.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2014.0159

EISSN

1540-1413

Publication Date

November 2014

Volume

12

Issue

11

Start / End Page

1590 / 1610

Location

United States

Related Subject Headings

  • Protein-Tyrosine Kinases
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Leukemia, Myeloid, Chronic-Phase
  • Leukemia, Myeloid, Accelerated Phase
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Guidelines as Topic
  • Antineoplastic Agents
  • 4203 Health services and systems